Although the causes are not completely understood, mental health patients also have increased risk factors for ischaemic heart disease, likely as a consequence of lifestyle and medication side-effects. 6 Currently there is little awareness of the risk of QT interval prolongation within this vulnerable patient cohort, either by the patients themselves, their medication prescribers within and outside the mental health system or within the mental health hospital staff. In fact, there is confusion within the literature with most research using variable methods of QT interval measurement and QTc threshold cut-offs, making comparison with other studies and clinically significant risk assessment difficult. Firstly, it is important to measure the QT interval manually. Studies have shown that the automated ECG measurement is inaccurate and can underestimate the QT interval. 7, 8 Secondly, corrected QT (QTc) intervals for heart rate (HR) such as Bazett's formula and Fridericia's formula are flawed, often over correcting in tachycardia and under-correcting in bradycardia when the patient is most at risk. 9 Rather, the most accurate method of assessing the QT interval is to use a standardised manual measurement method as published elsewhere, 10 with a plotted result on the QT nomogram. The QT nomogram is the most sensitive and specific method of clinically assessing the QT interval and avoids the use of HR correction. 11 The nomogram was derived from population data for QT:RR beat to beat variations and converted to a clinically user friendly QT:HR relationship. 12 The QT interval is plotted on the nomogram against the HR, and is abnormal if the result is above the 'at risk' line.
Our aim was to evaluate the assessment of QT prolongation within an Australian public inpatient mental health facility, by auditing the use of electrocardiograms (ECGs) during admission. Although the prevalence of QT prolongation in psychiatric inpatients has been looked at before [13] [14] [15] [16] [17] none of the studies have used a reliable measure of clinically significant QT abnormality.
Methods

Study design and setting
This study was a retrospective review of all mental health inpatient admissions to a large public, acute, adult, mental health inpatient facility. Every admission between 1 January 2016 and 11 February 2016 was reviewed and audited for the following data: demographic information (age and sex), medication history and current medication list and ECG during admission. All patient's electronic records were reviewed and all ECGs were manually read for QT interval length using a previously published method. 10 All patient records with an ECG were then reviewed for medications active on the same day as the ECG. Any medications listed as 'known risk of TdP' (red) on the CredibleMeds ® QTDrugs Lists 18 were recorded (Table 1) . Patients who were inpatients at the time of the assessment were followed up on the relevant unit.
Ethics was approved by the Hunter New England Research Ethics Committee (AU201605-07), who classified this study as an audit and waived the requirement for patient informed consent.
We applied descriptive statistics to present the data.
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Results
There were 263 mental health inpatient admissions between 1 January 2016 and 11 February 2016. Of these 263 admissions, 50 (19%) had an ECG during admission ( Figure 1 ).
The characteristics of the patients who had an ECG during admission were compared with those who did not receive an ECG (Table 2 ). The male-to-female ratio was similar; however, patients who received an ECG were more likely to be slightly older and have a longer length of stay.
Of the 50 presentations with an ECG, 4 (8%) showed an at-risk QT interval using the QT nomogram ( Figure 2 ). One QT:HR pair had a long QT but a heart rate of 116 beats per minute (bpm), where the QT nomogram has not been validated. The remaining 3 (or 6% of patients with an ECG) had HRs of 58, 82 and 79 bpm.
Of the 50 patients with an ECG, 12 (24%) patients were taking medication that is known to prolong the QT interval with a risk of TdP ( Table 1 ). The three patients who were found to have a long QT interval and a HR less than 105 bpm were all taking high-risk QT-prolonging agents ( Table 3 ). The patient with an abnormal QT interval and a HR of 116 bpm was on regular quetiapine and sertraline.
One patient during the study period suffered a cardiac event and died in hospital, but did not have an ECG performed during the admission.
Discussion
Our study showed that the rate of ECG screening for patients at risk of cardiac arrhythmias within a large public mental health inpatient facility is low. Only 50 patients from 263 had an ECG during their admission, which is less than 20% of all patients. Of the 50 patients who were screened, 8% had a prolonged QT interval, three-quarters of which were defined as at risk using the QT nomogram.
Patients appeared to be more likely to have an ECG performed if they were older, or had a longer length of stay. Whilst increasing age is a risk factor for QT prolongation and may have driven clinical decisions to do an ECG, the relationship with length of stay is likely to be more to do with opportunity to do an ECG than clinical need.
Of the small subset of patients who received an ECG during their inpatient admission, one-quarter (12/50) were noted to be on medication with the potential to prolong the QT interval. Of these 12 patients at increased risk secondary to medication, 3 patients had clinically significant QT prolongation on their ECG (Figure 1 ). This gives a rate of 25% of all patients on QT-prolonging agents who had an ECG having clinically significant QT prolongation.
There have been a number of other studies looking at the QT interval on ECGs in psychiatric inpatients. [13] [14] [15] [16] [17] Ozeki et al. 15 looked at the ECGs of 1071 Japanese psychiatric inpatient with schizophrenia, using Bazett's formula as a measure of the QT interval. They found a prevalence of QT prolongation of 2.5% in their patients and an association with increasing antipsychotic medication dose. Sadanaga et al. 16 showed a much more significant prevalence with 12% of psychiatric patients on psychotropic medication having a prolonged QT. Reilly et al. 17 showed a prevalence of QT prolongation of 8% in 495 psychiatric patients within hospital and the community. Ramos-Rios et al. 14 found a prevalence of 6% for QT prolongation in 171 patients with schizophrenia. The largest study of all, however, is by Girardin et al. 13 who screened the ECGs of all patients admitted to a major psychiatric hospital in Geneva for 5 years. From a total of 6790 included patients they found 1.6% of patients had a prolonged QT interval. Of the 0.9% (62 patients) specifically identified with long QT secondary to medication, 7 patients (20%) had an episode of TdP and 5 patients died from sudden cardiac death.
Another study has modelled the cost-effectiveness of screening all psychiatric inpatients for QT prolongation, finding it to be a cost-effective exercise. 19 Based on their model, 1128 patients would need to have ECG screening (with appropriate management of any abnormal findings) to prevent 1 episode of TdP and 2817 patients would need to be screened to prevent 1 death. Although large numbers of ECGs are required, they are a low-cost screening tool, and the model proved to be cost-effective at $US50,000 per quality adjusted life years saved.
There are a number of limitations with our study. Firstly, we do not know the reason some patients received an ECG and others did not and we can assume there was a bias towards ordering an ECG in patients with some sort of increased risk. There is not enough evidence available, as yet, to safely guide clinical recommendations on what to do if an at-risk QT prolongation is found; however, it would be wise to investigate for potentially reversible contributors to a long QT interval, such as electrolyte imbalance, and reverse these where possible. When a drug is deemed likely responsible, then it is up to the treating doctor and patient to make a decision regarding the potential risks of arrhythmia versus the clinical benefit of the medication for that individual patient.
In summary, this small study shows when the QT is measured accurately and appropriate risk assessment tools are used there is a 6% prevalence of clinically significant QT prolongation within an Australia public hospital psychiatric inpatient facility.
Our study needs to be expanded with prospective ECG screening of all inpatient admissions and concomitant review of their medication. This would allow a better assessment of the significance of the problem.
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